NDA 210656 · Pfizer
Daurismo
Glasdegib Maleate · Oral · Hedgehog Pathway Inhibitor
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Mar 27, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Nov 21, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
29
5 Phase 3, 1 recruiting
FAERS reports
474
443 serious, 193 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: EMBRYO-FETAL TOXICITY DAURISMO can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. DAURISMO is embryotoxic, fetotoxic, and teratogenic in animals [see Warnings and Precautions (5.1) , Use in Specific Populations (8.1) ] . Conduct pregnancy testing in females of reproductive potential prior to initiation of DAURISMO treatment. Advise females of reproductive potential to use effective contraception during treatment with DAURISMO and for at least 30 days after the last dose [see Warnings and Precautions (5.1) , Use in Specific Populations (8.1 , 8.3) ] . Advise males of the potential risk of DAURISMO exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential during treatment with DAURISMO and for at least 30 days after the last dose to avoid potential drug exposure [see Warnings and...
What it is approved for
From the label in effect Dec 12, 2025.
DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy. DAURISMO is a hedgehog pathway inhibitor indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy. ( 1 )
Mechanism: Glasdegib is an inhibitor of the Hedgehog pathway. Glasdegib binds to and inhibits Smoothened, a transmembrane protein involved in hedgehog signal transduction. In a murine xenotransplant model of human AML, glasdegib in combination with low-dose cytarabine, inhibited increases in tumor size and reduced the percentage of CD45+/CD33+ blasts in the marrow to a greater extent than glasdegib or low-dose cytarabine alone.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 21, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
2 products under this application
- DAURISMO · GLASDEGIB MALEATE EQ 100MG BASE · TABLET, ORAL · Prescription
- DAURISMO · GLASDEGIB MALEATE EQ 25MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Glasdegib" as an intervention, any sponsor and status, largest first.
- A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid LeukemiaPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03416179 · 730 participants · Start Apr 20, 2018 · Primary completion Jun 5, 2020
Drug: glasdegib; daunorubicin + cytarabine and 5 more · For: Leukemia, Myeloid, Acute
Sites: Los Angeles, California; Orange, California; San Francisco, California · 149 sites in all
- Molecular Profiling of Advanced Soft-tissue SarcomasPivotal-lookingCompleted
Institut National de la Santé Et de la Recherche Médicale, FranceGovernment (non-federal)
NCT03784014 · 603 participants · Start Oct 19, 2019 · Primary completion Dec 1, 2023
Drug: Nilotinib; Ceritinib and 6 more · For: Soft Tissue Sarcoma
Sites: Bordeaux, France; Dijon, France; Lille, France · 17 sites in all
- IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.Pivotal-lookingRecruiting
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSAcademic, hospital or other
NCT06713837 · 339 participants (planned) · Start Feb 27, 2025 · Primary completion Jan 2028
Drug: High intensity therapies; Low intensity therapies · For: Acute Myeloid Leukemia; Relapse/Recurrence
Sites: Brno, Czechia; Hradec Králové, Czechia; Olomouc, Czechia · 51 sites in all
- A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01546038 · 255 participants · Start Jun 27, 2012 · Primary completion Jan 3, 2017
Drug: PF-04449913; Low dose ARA-C (LDAC) and 10 more · For: Acute Myeloid Leukemia
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 81 sites in all
Grupo Español de Investigación en NeurooncologíaAcademic, hospital or other
NCT03466450 · 75 participants · Start Mar 15, 2018 · Primary completion Nov 29, 2023
Drug: PF-04449913; Temozolomide Oral Capsule · For: Glioblastoma
Sites: Badalona, Spain; Barcelona, Spain; Girona, Spain · 8 sites in all
University of NebraskaAcademic, hospital or other
NCT03226418 · 75 participants · Start Jul 7, 2017 · Primary completion Mar 16, 2024
Drug: Cytarabine; Decitabine and 5 more · For: Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Therapy-Related Acute Myeloid Leukemia
Sites: Omaha, Nebraska
PfizerPfizer (PFE)
NCT02367456 · 73 participants · Start Apr 28, 2015 · Primary completion Jan 29, 2020
Drug: PF-04449913 (Glasdegib); Azacitidine · For: Myelodysplastic Syndrome; Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia
Sites: Birmingham, Alabama; La Jolla, California; New Haven, Connecticut · 33 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT03390296 · 50 participants · Start Dec 27, 2017 · Primary completion Feb 4, 2022
Drug: Anti-OX40 Agonist Monoclonal Antibody PF-04518600; Avelumab and 6 more · For: Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
Sites: Houston, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death111
- febrile neutropenia69
- pneumonia48
- off label use34
- neoplasm progression28
- neutropenia24
- sepsis15
- toxicity to various agents13
- electrocardiogram qt prolonged12
- product use in unapproved indication11
- septic shock11
- decreased appetite10
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2018 | 13 |
| 2019 | 116 |
| 2020 | 121 |
| 2021 | 107 |
| 2022 | 45 |
| 2023 | 20 |
| 2024 | 22 |
| 2025 | 17 |
| 2026 | 8 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Daurismo (Glasdegib Maleate)
2024 spending
$3.7M
Beneficiaries
75
174 claims
Per beneficiary
$48,711
$653.50 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,592,363 |
| 2021 | $4,716,600 |
| 2022 | $4,576,168 |
| 2023 | $2,942,885 |
| 2024 | $3,653,309 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia.
Norsworthy KJ, By K, Subramaniam S, et al. · Clin Cancer Res 2019 · Clinical Trial, Phase II, Multicenter Study
- Glasdegib in the treatment of acute myeloid leukemia.
Wolska-Washer A, Robak T · Future Oncol 2019 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Indirect treatment comparison of ivosidenib and other therapies in patients with newly diagnosed acute myeloid leukemia.
Gil-Sierra MD, Mantopoulos T, Barouma I, et al. · Future Oncol 2025 · Systematic Review, Comparative Study
- Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials.
Cortes JE, Dombret H, Merchant A, et al. · Future Oncol 2019 · Clinical Trial, Phase III, Randomized Controlled Trial
- Glasdegib in combination with temozolomide and radiotherapy in adult patients with newly diagnosed glioblastoma: the phase Ib/II GEINO 1602 trial.
Vaz-Salgado MÁ, Del Barco S, Sepúlveda JM, et al. · Nat Commun 2025 · Clinical Trial, Phase II, Clinical Trial, Phase I
- Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials.
Rodríguez-Arbolí E, Lee CJ, Caballero-Velázquez T, et al. · Clin Cancer Res 2023 · Clinical Trial, Phase II, Clinical Trial, Phase I
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.